How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse

被引:98
作者
Godfrey, Caroline [1 ]
Muses, Sofia [2 ]
McClorey, Graham [1 ]
Wells, Kim E. [2 ]
Coursindel, Thibault [3 ,4 ]
Terry, Rebecca L. [2 ]
Betts, Corinne [1 ]
Hammond, Suzan [1 ]
O'Donovan, Liz [3 ]
Hildyard, John [2 ]
El Andaloussi, Samir [1 ,5 ]
Gait, Michael J. [3 ]
Wood, Matthew J. [1 ]
Wells, Dominic J. [2 ]
机构
[1] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3QX, England
[2] Royal Vet Coll, Dept Comparat Biomed Sci, London NW1 0TU, England
[3] MRC, Mol Biol Lab, Cambridge CB2 0QH, England
[4] GENEPEP SA, F-34430 St Jean De Vedas, France
[5] Karolinska Inst, Dept Lab Med, SE-14186 Huddinge, Sweden
基金
英国医学研究理事会; 英国惠康基金;
关键词
DUCHENNE MUSCULAR-DYSTROPHY; FULL-LENGTH; MUSCLE PATHOLOGY; ANTISENSE OLIGONUCLEOTIDES; DISEASE PROGRESSION; EXPRESSION; MICE; RESTORATION; PHENOTYPE; RNA;
D O I
10.1093/hmg/ddv155
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Splice modulation therapy has shown great clinical promise in Duchenne muscular dystrophy, resulting in the production of dystrophin protein. Despite this, the relationship between restoring dystrophin to established dystrophic muscle and its ability to induce clinically relevant changes in muscle function is poorly understood. In order to robustly evaluate functional improvement, we used in situ protocols in the mdx mouse to measure muscle strength and resistance to eccentric contraction-induced damage. Here, we modelled the treatment of muscle with pre-existing dystrophic pathology using antisense oligonucleotides conjugated to a cell-penetrating peptide. We reveal that 15% homogeneous dystrophin expression is sufficient to protect against eccentric contraction-induced injury. In addition, we demonstrate a >40% increase in specific isometric force following repeated administrations. Strikingly, we show that changes in muscle strength are proportional to dystrophin expression levels. These data define the dystrophin restoration levels required to slowdown or prevent disease progression and improve overall muscle function once a dystrophic environment has been established in the mdx mouse model.
引用
收藏
页码:4225 / 4237
页数:13
相关论文
共 47 条
[1]   Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials [J].
Anthony, Karen ;
Cirak, Sebahattin ;
Torelli, Silvia ;
Tasca, Giorgio ;
Feng, Lucy ;
Arechavala-Gomeza, Virginia ;
Armaroli, Annarita ;
Guglieri, Michela ;
Straathof, Chiara S. ;
Verschuuren, Jan J. ;
Aartsma-Rus, Annemieke ;
Helderman-van den Enden, Paula ;
Bushby, Katherine ;
Straub, Volker ;
Sewry, Caroline ;
Ferlini, Alessandra ;
Ricci, Enzo ;
Morgan, Jennifer E. ;
Muntoni, Francesco .
BRAIN, 2011, 134 :3544-3556
[2]   In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52-Deficient mdx Mouse [J].
Aoki, Yoshitsugu ;
Nakamura, Akinori ;
Yokota, Toshifumi ;
Saito, Takashi ;
Okazawa, Hitoshi ;
Nagata, Tetsuya ;
Takeda, Shin'ichi .
MOLECULAR THERAPY, 2010, 18 (11) :1995-2005
[3]   Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression [J].
Arechavala-Gomeza, V. ;
Kinali, M. ;
Feng, L. ;
Brown, S. C. ;
Sewry, C. ;
Morgan, J. E. ;
Muntoni, F. .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2010, 36 (04) :265-274
[4]   Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment [J].
Betts, Corinne ;
Saleh, Amer F. ;
Arzumanov, Andrey A. ;
Hammond, Suzan M. ;
Godfrey, Caroline ;
Coursindel, Thibault ;
Gait, Michael J. ;
Wood, Matthew J. A. .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2012, 1 :e38
[5]  
Boisguerin P., 2015, ADV DRUG DELIV REV, V4
[6]   Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse [J].
Briguet, A ;
Courdier-Fruh, I ;
Foster, M ;
Meier, T ;
Magyar, JP .
NEUROMUSCULAR DISORDERS, 2004, 14 (10) :675-682
[7]   X-CHROMOSOME-LINKED MUSCULAR-DYSTROPHY (MDX) IN THE MOUSE [J].
BULFIELD, G ;
SILLER, WG ;
WIGHT, PAL ;
MOORE, KJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (04) :1189-1192
[8]   miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy [J].
Cacchiarelli, Davide ;
Incitti, Tania ;
Martone, Julie ;
Cesana, Marcella ;
Cazzella, Valentina ;
Santini, Tiziana ;
Sthandier, Olga ;
Bozzoni, Irene .
EMBO REPORTS, 2011, 12 (02) :136-141
[9]   Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study [J].
Cirak, Sebahattin ;
Arechavala-Gomeza, Virginia ;
Guglieri, Michela ;
Feng, Lucy ;
Torelli, Silvia ;
Anthony, Karen ;
Abbs, Stephen ;
Garralda, Maria Elena ;
Bourke, John ;
Wells, Dominic J. ;
Dickson, George ;
Wood, Matthew J. A. ;
Wilton, Steve D. ;
Straub, Volker ;
Kole, Ryszard ;
Shrewsbury, Stephen B. ;
Sewry, Caroline ;
Morgan, Jennifer E. ;
Bushby, Kate ;
Muntoni, Francesco .
LANCET, 2011, 378 (9791) :595-605
[10]   THE MDX MOUSE SKELETAL-MUSCLE MYOPATHY .1. A HISTOLOGICAL, MORPHOMETRIC AND BIOCHEMICAL INVESTIGATION [J].
COULTON, GR ;
MORGAN, JE ;
PARTRIDGE, TA ;
SLOPER, JC .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1988, 14 (01) :53-70